RedHill Biopharma Ltd. (RDHL)

RedHill Biopharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Net Income	23.92	-71.67	-97.74	-76.17	-42.3
Depreciation & Amortization	1.99	8.15	18.15	8.75	1.21
Share-Based Compensation	1.65	5.68	10.21	4.2	3.03
Other Operating Activities	-63.37	28.66	4.34	14.65	-2.69
Operating Cash Flow	-35.82	-29.19	-65.05	-48.58	-40.75
Capital Expenditures	-0.01	-0.2	-0.12	-0.41	-0.17
Change in Investments	0.02	8.5	-8.03	18.13	5.37
Other Investing Activities	-	-	-	-53.37	-0.04
Investing Cash Flow	0	8.3	-8.14	-35.65	5.16
Share Issuance / Repurchase	13.96	23.81	78.54	23.87	36.3
Debt Issued / Paid	-1.18	-1.48	-1.68	76.45	-0.8
Other Financing Activities	8.66	-10.88	-3.39	-15.95	0.01
Financing Cash Flow	21.44	11.45	73.46	84.37	35.51
Exchange Rate Effect	-0.02	-0.08	-0.1	0.13	0.09
Net Cash Flow	-14.38	-9.43	0.28	0.14	-0.08
Free Cash Flow	-35.83	-29.38	-65.16	-48.99	-40.92
Free Cash Flow Margin	-548.71%	-47.55%	-75.98%	-76.11%	-650.41%
Free Cash Flow Per Share	-11.21	-18.41	-55.70	-55.55	-57.69

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).